Although cardiovascular disease (CVD) is the leading cause of mortality globally, it remains insufficiently understood in large parts of the world. The scientific foundations underpinning CVD risk prediction, diagnostics, and treatment are extensively derived from homogenous datasets, primarily including White, male participants from high-income countries. This lack of diversity and inclusion can lead to biased evidence, which in turn contributes to reduced diagnostic accuracy and the under-representation of key populations, and ultimately limits the generalizability of trial results and guidelines. In this paper, we discuss that diversity in cardiovascular data is a scientific necessity for valid and globally applicable knowledge and not just a matter of fairness. Drawing from emerging initiatives in genomics, digital health, and participatory research, we propose a global roadmap to reshape how cardiovascular research is conducted. This includes strategies such as data donation frameworks, inclusive biobanking, equitable AI development, and international policy change. Only by integrating diversity into scientific methodologies can we ensure that cardiovascular guidelines are effective, inclusive, and just.
Grewal et al. (Sat,) studied this question.